The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.
New research suggests that even previous non-responders to Hepatitis C treatment could benefit from the medications they once took.
Continue reading »Based on a chimpanzee study, scientists have found that a high dose of human monoclonal antibody targeting Hepatitis C delivered protection against this potent liver virus.
Continue reading »In Israel, Medgenics has been approved to deliver a naturally-produced interferon alpha for Hepatitis C via a biopump in trials for treatment naïve patients and those who have previously relapsed.
Continue reading »Because of its likeness to Bristol-Myers' Hepatitis C drug that was associated with heart problems, Idenix's IDX19368 has been placed on a clinical hold by the FDA.
Continue reading »Despite paying big money for BMS-986094, Bristol-Myers has suspended testing on this experimental medicine for Hepatitis C after one person developed heart failure and eight others were hospitalized.
Continue reading »A National Institutes of Health study predicts who will develop advanced fibrosis and cirrhosis rapidly from Hepatitis C infection.
Continue reading »Although requiring further investigation, a study has demonstrated Vitamin B12 as capable of boosting the success of Hepatitis C treatment.
Continue reading »In a mid-stage trial, Achillion's experimental drug, sovaprevir, demonstrated an excellent efficacy rate and safety profile.
Continue reading »Trials on one of Bristol-Myers' potential Hepatitis C drugs, BMS-986094, have been halted to investigate a possible case of related heart failure.
Continue reading »A study published in the online journal Hepatology reports a potential new NADPH oxidase (NOX) inhibitor therapy for liver fibrosis, a scarring process associated with chronic liver disease that can lead to loss of liver function.
Continue reading »Inside you'll discover:
You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.
You should receive your email with links to the reports shortly. If you do not, please check your spam/junk folder.
If you still haven't received our email after a few minutes, please feel free to contact us.
Close Window
